“We are also planning a potential registrational study in adults later this year with our fourth-generation PCB candidate.”

In context

“the opportunity to change the standard of care globally for IBC Express in human. Both these ADCs, PDL1V, and SVB are potential first-in-class ADCs using payload that elicits immunogenic cell death. And in combination with any new checkpoint inhibitor demonstrates significant results. Early data for PDL1V and SV in combination with pembrolizumab are highly encouraged. With both ADCs, we are targeting non-small cell lung cancer, the most frequently diagnosed cancer globally, and the leading cause of cancer-related deaths. Lung cancer represents a substantial area of patient need and a growing market with the highest projected CAGR in oncology through 2030. In vaccines, another of our priority therapeutic areas, we see opportunities to enhance and augment our strong positions in the market. We are also planning a potential registrational study in adults later this year with our fourth-generation PCB candidate. With our fourth and fifth-generation PCV candidates, we believe we can build on our leadership in the industry. Our fourth-generation candidate covers twenty-five serotypes, including potentially improved immunogenicity for serotype three, which is one of the largest remaining contributors of disease. We are also working to accelerate progress with our fifth-generation candidate, which is in preclinical development and covers over thirty serotypes. As we continue to scrutinize the number of programs we are actively advancing, we will have opportunities to accelerate or add others to help address significant patient needs. One example is the recent accelerated start of a pivotal study for Norte for menstruation-related migraine, which is estimated to impact more than half of women who expe”